FN1 and mesenchymal cell neoplasm: They have shown that when CRC patients are classified as mesenchymal (CMS4) versus non-mesenchymal (neither CMS4), the risk of poor prognosis in patients with mesenchymal tumors and high-abundance FN is approximately two-fold.